CSIMarket
 
Indaptus Therapeutics Inc   (NASDAQ: INDP)
 
Price: $2.5600 $0.48 23.077%
Day's High: $2.630000114440918 Week Perf: 120.69 %
Day's Low: $ 1.97 30 Day Perf: 115.13 %
Volume (M): 3,141,442 52 Wk High: $ 8.57
Volume (M$): $ 0 52 Wk Avg: $2.38
Open: $2.00 52 Wk Low: $0.92



 Market Capitalization (Millions $) 297
 Shares Outstanding (Millions) 116
 Employees 5
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -15
 Cash Flow (TTM) (Millions $) -5
 Capital Exp. (TTM) (Millions $) 0

Business Description


Indaptus Therapeutics Inc is a pharmaceutical company that focuses on developing innovative therapies for the treatment of various diseases. The company's main area of expertise lies in the field of gene therapy and genetic medicine.

Indaptus Therapeutics Inc utilizes cutting-edge technology and research to identify and develop gene therapies that target specific genetic mutations and diseases. This approach holds great potential for the treatment of genetic disorders that currently have limited or no treatment options.

The company's goal is to bring forward transformative therapies that can improve patient outcomes and quality of life. Indaptus Therapeutics Inc collaborates with leading academic institutions and research organizations to advance its pipeline of therapeutics.

With a strong focus on precision medicine, Indaptus Therapeutics Inc aims to develop personalized therapies that are tailored to individual patients' genetic profiles. This approach has the potential to revolutionize the way diseases are treated by addressing the underlying genetic causes.

Overall, Indaptus Therapeutics Inc is dedicated to pushing the boundaries of medicine and making a lasting impact in the field of gene therapy, with the ultimate objective of improving the lives of patients suffering from genetic diseases.


   Company Address: 3 Columbus Circle New York 10019 NY
   Company Phone Number: 427-2727   Stock Exchange / Ticker: NASDAQ INDP


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
JNJ   -3.22%    
MRK   -4.57%    
PFE   -4.74%    
TEVA   -3.04%    
VRTX   -6.91%    
VTRS   -4.15%    
• View Complete Report
   



Shares

Indaptus Therapeutics Bolsters Financial Position Through Strategic Private Placement Amid Promising Cancer Immunotherapy Developments

Published Mon, Jan 13 2025 1:02 PM UTC

Indaptus Therapeutics Strengthens Its Footing: A ...

Management Announcement

Indaptus Therapeutics Reports Promising Immunotherapy Advances Amidst Financial Struggles,

Published Mon, Nov 11 2024 1:00 PM UTC

Indaptus Therapeutics Inc. a leader in immunotherapy innovation, has made significant strides with its cutting-edge Decoy platform, which focuses on combating cancer through novel immunotherapeutic approaches. Recently, the company published preclinical data in the peer-reviewed journal Frontiers in Immunology , shedding light on the single-agent anti-tumor activity of thei...

Clinical Study

Indaptus Therapeutics Decoy20 Pioneering Immunotherapy with the Pulse-Prime Breakthrough,

Published Thu, Nov 7 2024 1:00 PM UTC

Exploring New Frontiers: Indaptus Therapeutics Unveils Promising Phase 1 Trial Results for Decoy20 and Validates Pulse-Prime Hypothesis at SITC 2024 Indaptus Therapeutics, a pioneering force in the field of immunotherapy, has recently unveiled promising interim safety data from their Phase 1 clinical trial of Decoy20 at the prestigious Society for Immunotherapy of Cancer (SI...

Clinical Study

Decoy20 Advances Indaptus Therapeutics Unveils Encouraging Safety Data and Expands Enrollment to Redefine Cance...

Published Thu, Sep 5 2024 12:31 PM UTC

:Indaptus Therapeutics, Inc. (Nasdaq: INDP), a clinical-stage biotechnology company renowned for developing groundbreaking treatments for cancer and viral infections, recently disclosed promising new safety data pertaining to its Decoy20 clinical program. Driven by these encouraging results, the company has commenced an expanded patient enrollment initiative for weekly dosi...

Management Announcement

Indaptus Therapeutics, Inc. Raises $3.0 Million to Drive Innovation in Cancer and Viral Infection Treatments, refusal: null

Published Wed, Aug 7 2024 11:01 AM UTC

Indaptus Therapeutics, Inc. Secures $3.0 Million in Funding for Groundbreaking Cancer and Viral Infection Treatments
August 7, 2024 - Indaptus Therapeutics, Inc. (Nasdaq: INDP), a pioneering clinical stage biotechnology company, announced today the successful completion of a $3.0 million registered direct offering and concurrent private placement. This funding milestone ...




Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) -
Price to Sales (Expected) -
Price to Book 26.14
PEG (TTM) -

Financial Strength Current
Quick Ratio 29.61
Working Capital Ratio 31.21
Leverage Ratio (MRQ) 0.05
Total Debt to Equity 0
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) -11.63 $
Revenues (TTM) -
Cash Flow (TTM) -
Cash 0.13 $
Book Value 0.1 $
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) -
Net Income per Employee (TTM) -3,084,700
Receivable Turnover Ratio (TTM) -
Inventory Turnover Ratio (TTM) -
Asset Turnover Ratio (TTM) -

Profitability Ratios Current
Gross Margin (MRQ) -
Operating Margin (MRQ) -
Net Margin (MRQ) -
Net Cash Flow Margin (MRQ) -
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -






Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.